A Challenging Case of Advanced Cardiac Sarcoidosis Refractory to Infliximab Therapy.

Cardiac sarcoidosis can be life-threatening, and lack of response to immunosuppressive therapy remains a significant challenge in active disease. We present a case of refractory cardiac sarcoidosis despite third-line immunosuppression (infliximab). Ongoing multimodality assessment is essential for managing refractory cardiac sarcoidosis.